TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01993368

Intervention type: OTHER
Group type: OTHER
Intervention: flow cytometry
Description: These populations will be identified by different combinations of antibodies to identify:~* T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).~* Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)~* Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)

Intervention type: OTHER
Group type: OTHER
Intervention: flow cytometry
Description: These populations will be identified by different combinations of antibodies to identify:~* T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).~* Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)~* Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)

Intervention type: OTHER
Group type: OTHER
Intervention: flow cytometry
Description: These populations will be identified by different combinations of antibodies to identify:~* T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).~* Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)~* Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)
Study: NCT03324009

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2-stage screen
Description: Pap smear is currently the standard of care for cervical cancer screening in Botswana. In this study, participants will undergo HPV DNA testing at the time of Pap smear collection. If HPV DNA test is positive, they will be referred for colposcopy. Patients who have an HPV negative test but positive Pap smear will be referred for colposcopy per Botswana cervical cancer screening guidelines.
Study: NCT04069520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aNMT Biofeedback
Description: aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention. The aNMT biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Biofeedback
Description: Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases. The sham biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks.
Study: NCT01068912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo BID x 1 day, and Placebo BID x 4 days
Study: NCT03634150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.
Description: Once weekly treatment, with IV doses of Nerofe (96mg\\m2) and low dose (20 mg/m2) Doxorubicin 5 or 24 hours from one another) .
Study: NCT01784536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-Dose IV Oritavancin Diphosphate
Description: Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
Study: NCT00309244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation Powder
Description: Inhalation, 15U/30U

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Description: BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
Study: NCT03211832

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dissemination of public health knowledge
Description: Participating local health departments will help develop and choose dissemination strategies they prefer for their staff working in and supporting diabetes and chronic disease prevention and control to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes prevention and control.
Study: NCT00857051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hotline Service
Description: A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hotline Service
Description: A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Film
Description: A DVD addressing common stressors in the early postpartum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Film
Description: A DVD addressing common stressors in the early postpartum.
Study: NCT04353947

Intervention type: DIAGNOSTIC_TEST
Intervention: Global Deterioration Scale (GDS)
Description: This scale measures the level of deterioration of the subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: Memory alteration test (M@T)
Description: In this test different memory subtypes are evaluated.
Study: NCT04039750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic rinse with suction
Description: antibiotic rinse with suction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suction only
Description: no irrigation, suction only
Study: NCT02179658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPT-80
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: oral
Study: NCT02988960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous
Study: NCT00656812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on day 1 of a 21-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-CdA
Description: 0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
Study: NCT04359615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Favipiravir in COVID-19 patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study: NCT02455011

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: REMD-477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477
Study: NCT04353947

Intervention type: DIAGNOSTIC_TEST
Intervention: Auto-Assessment Manikins (SAM)
Description: It is a self-report questionnaire that assesses the emotional response of the subject, in this case, through a mood induction task that plays different films scenes.
Study: NCT02464358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB Intervention Group
Description: Participants in the IMB group received information specific to HPV, cervical cancer, and the HPV vaccine. This information was delivered in a group setting, and it was delivered via a PowerPoint presentation that included short video clips.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants in the attention control arm watched a PowerPoint that contained a series of short video clips encompassing aspects of women's general and sexual health. This was also conducted in a group setting.
Study: NCT02846428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-FU will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle during neoadjuvant treatment period for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered at 900 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered at 100 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered at 100 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin will be administered at 100 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin will be administered at 100 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
Study: NCT04331405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Allogeneic Umbilical Cord Blood Mononuclear Cells (hUCBMCs) systemic (i.v.) infusions
Description: HUCBMCs samples were prepared for infusion in the specialized laboratory of Cord Blood Bank (CryoCenter Ltd) and transported to the clinic immediately within 2 hours in the Dry Shipper. All samples were chosen according to patients blood group and rhesus-factor.~All samples were examined for hemotransmissive infections and cell viability prior to the preparation.~Obtained samples were infused through the blood transfusion systems with additional filter after 3 tests for biological and individual compatibility and tolerance.~Each patient of the pilot group received 4 cell infusions (1 infusion per week) with 1 week interval during the in-hospital treatment.
Study: NCT02370862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine and Glycopyrrolate
Study: NCT01501097

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Continuous Renal Replacement Therapy
Description: Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
Study: NCT04255134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection
Description: Subjects will be randomized to treatment with either abatacept or adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab Injection
Description: Subjects will be randomized to treatment with either abatacept or adalimumab
Study: NCT01501097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy
Description: Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
Study: NCT01641432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tonic and Phasic Attention Training
Description: The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).~Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes.
Study: NCT01233726

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: T-Diet plus Diabet IR
Description: Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ISOSOURCE PROTEIN FIBRE
Description: Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
Study: NCT01641432

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
Study: NCT01205308

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vegetable oil based margarine with plant stanol ester enrichment
Description: 3 g plant stanols/ day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable oil based margarine with plant stanol ester enrichment
Description: 3 g plant stanols/ day
Study: NCT04679246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory intervention
Description: Surveillance in compliance with the regulation of the sale of food in school buildings, according to official guidelines Training for the preparation of hygienic and healthy food for the personnel in charge of food sale Promotion of the consumption of simple water and healthy foods Reconditioning of the infrastructure for the consumption of simple water, free and healthy food, and the realization of physical activity Organization of events and support in the coordination of groups that promote physical activity at the community level Optimization of physical education classes at school sites Implementation of health promotion and care actions in the school context Development of skills in the school community for health care and generation of healthy school environments Creation and strengthening of health and nutrition committees in schools, with the participation of directors, teachers and parents to generate necessary and permanent conditions that favor healthy environments

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory intervention
Description: Surveillance in compliance with the regulation of the sale of food in school buildings, according to official guidelines Training for the preparation of hygienic and healthy food for the personnel in charge of food sale Promotion of the consumption of simple water and healthy foods Reconditioning of the infrastructure for the consumption of simple water, free and healthy food, and the realization of physical activity Organization of events and support in the coordination of groups that promote physical activity at the community level Optimization of physical education classes at school sites Implementation of health promotion and care actions in the school context Development of skills in the school community for health care and generation of healthy school environments Creation and strengthening of health and nutrition committees in schools, with the participation of directors, teachers and parents to generate necessary and permanent conditions that favor healthy environments
Study: NCT02874352

Intervention type: DEVICE
Group type: OTHER
Intervention: high resolution impedance manometry with Automated Impedance Manometry analysis

Intervention type: DEVICE
Group type: OTHER
Intervention: high resolution impedance manometry with Automated Impedance Manometry analysis
Study: NCT03409458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT-112
Description: The RP2D of PT-112 when used in combination with avelumab has been determined during dose escalation and is being confirmed in the NSCLC dose confirmation cohort.~For the NSCLC confirmation cohort, PT-112 will be administered at a dose of 360 mg/m2 on Days 1, 8 and 15.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Avelumab will be administered at a fixed dose of 800 mg on Days 1 and 15.
Study: NCT03360669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence: Clinical/Research
Description: Participants will be assigned to a sequence of: research visit first/clinical visit second.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sequence: Research/Clinical
Description: Participants will be assigned to a sequence of: clinical visit first/research visit second.
Study: NCT01233726

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GLUCERNA SELECT
Description: Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
Study: NCT03946267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inverted inner limiting membrane flap technique for large full thickness macular holes
Description: The ILM, stained with IFCG or BBG, is peeled off with ILM forceps, usually beginning near the inferotemporal vascular arcade, at least 2 disk diameters from the macular hole, in a circular manner. The peeling is extended up to the edges of the macular hole, the wide ILM flap obtained reduced by trimming with the vitreous cutter, and the annular remnant of ILM hinged to the hole's edge gently inverted upside down facing the RPE. Therefore, the hole is covered with usually more layers of inverted ILM. Attention is paid to avoid insertion and filling of the hole volume with ILM.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inverted inner limiting membrane flap technique for large full thickness macular holes
Description: The ILM, stained with IFCG or BBG, is peeled off with ILM forceps, usually beginning near the inferotemporal vascular arcade, at least 2 disk diameters from the macular hole, in a circular manner. The peeling is extended up to the edges of the macular hole, the wide ILM flap obtained reduced by trimming with the vitreous cutter, and the annular remnant of ILM hinged to the hole's edge gently inverted upside down facing the RPE. Therefore, the hole is covered with usually more layers of inverted ILM. Attention is paid to avoid insertion and filling of the hole volume with ILM.
Study: NCT02632825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow
Description: Nasal High Flow Therapy
Study: NCT02111538

Intervention type: OTHER
Intervention: Dietary advice
Description: Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for
Study: NCT02544724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NM-IL-12
Description: Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
Study: NCT04686890

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinea plane block administered preoperative open nephrectomy
Description: erector spinae plane block applied in this group before open nephrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinea plane block administered preoperative open nephrectomy
Description: erector spinae plane block applied in this group before open nephrectomy
Study: NCT01514175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ibuprofen
Description: Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ketorolac
Description: Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
Study: NCT00668408

Intervention type: OTHER
Group type: OTHER
Intervention: LTOT (oxygen therapy)
Description: Patients on LTOT will receive oxygen for at least 15 hours/day from the liquid oxygen systems at a flow rate adjusted to raise resting SaO2 between 93 and 96% and / or PaO2 between 65 and 80 mmHg every day for 3 years.

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacological therapy of COPD and CHF
Description: Optimal pharmacologic treatment will include :~* Long (LABD, salmeterol, formoterol, tiotropium) - as well as short-acting (SABD, Salbutamol, terbutaline, ipratropium)bronchodilators (beta-2 agonists, anticholinergics)~* Inhaled steroids (ICS, beclomethasone, fluticasone, budesonide always associated with LABD)~* Beta-blockers~* Diuretics~* Angiotensin-converting enzyme (ACE) inhibitors alone or in associations with diuretics~* Statins and any other treatment required for associated co-morbidities (eg insulin and/or anti-diabetic drugs, other antihypertensive, etc).~The treatment of the deseases will follow the international guidelines.
Study: NCT02712242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after PRF placing on palatal wounds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Butyl cyanoacrylate
Description: Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after Butyl Cyanoacrylate application on palatal wounds.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wet gauze
Description: Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after wet gauze pressure on palatal wounds.